Results 51 to 60 of about 27,792 (251)

Plasma and breast milk pharmacokinetics of suvorexant in healthy lactating women

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This paper aims to evaluate the plasma and breast milk pharmacokinetics of suvorexant, an orexin receptor antagonist used to treat insomnia at a maximum dose of 20 mg, in healthy lactating women. Methods The paper reports on an open‐label Phase 1 study in 12 healthy lactating women.
Jacqueline McCrea   +10 more
wiley   +1 more source

Cyp2c19 Genotypes in the Pharmacokinetics/Pharmacodynamics of Proton Pump Inhibitor-Based Therapy of Helicobacter Pylori Infection

open access: yes, 2011
importance of the field. Proton pump inhibitors (PPIs) are potent gastric acid inhibitors. Therapies with a PPI and antibiotics are used to cure Helicobacter pylori (H. pylori) infection, which is closely related to many gastrointestinal diseases.
楊智欽;林君榮   +1 more
core   +1 more source

Metabolic activation of aegeline mediated by CYP2C19

open access: yesXenobiotica, 2021
Aegeline (AGL) is a natural alkaloidal amide mainly isolated from the leaves and fruits of tropical plant Aegle marmelos, with multiple pharmacological activities.As one component of several dietary supplements, AGL caused a series of acute and chronic liver injuries. Nevertheless, the mechanisms of AGL-induced hepatotoxicity remain unclear. This study
Min, Tian   +6 more
openaire   +2 more sources

New therapeutic options for metabolic‐associated steatotic liver disease

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

In vitro assessment of the impact of 30 CYP2C19 variants on citalopram metabolism [PDF]

open access: yesPeerJ
Background CYP2C19 polymorphisms are correlated with individual variability in response to citalopram treatment. The pharmacogenomic testing of CYP2C19 has been shown to optimize the safety and efficacy of citalopram medication. Exploration of the effect
Peng Wang, Xiao-xia Hu, Jun-wei Li
doaj   +2 more sources

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza   +12 more
wiley   +1 more source

The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles [PDF]

open access: yesDrug Metabolism and Disposition, 2015
CYP2C19 rs12769205 alters an intron 2 branch point adenine leading to an alternative mRNA in human liver with complete inclusion of intron 2 (exon 2B). rs12769205 changes the mRNA reading frame, introduces 87 amino acids, and leads to a premature stop codon. The 1000 Genomes project (http://browser.1000genomes.org/index.html) indicated rs12769205 is in
Amarjit S, Chaudhry   +11 more
openaire   +2 more sources

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen   +17 more
wiley   +1 more source

Predictors of angina pain relapse after coronary stenting for acute coronary syndrome in Buryats

open access: yesРоссийский кардиологический журнал, 2023
Aim. To identify and rank factors predisposing to angina relapse in Buryat patients who underwent percutaneous intervention for acute coronary syndrome.Material and methods. The study included 142 Buryat patients who underwent coronary stenting for acute
E. M. Zelenskaya   +6 more
doaj   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy